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Abstract
Background: Statins reduce plasma low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive
protein (hsCRP) levels. Rosuvastatin 10 mg daily appears to be more potent in reducing LDL-C than simvastatin
40 mg, but the relative effect of these two statin doses on hsCRP is unknown.
Methods: Chinese hyperlipidaemic patients with high cardiovascular risk or familial hypercholesterolaemia (FH)
were treated with rosuvastatin 10 mg and simvastatin 40 mg daily in an open-label crossover study. Lipid profiles
were measured off treatment and after at least 4 weeks treatment with each of the two statins and hsCRP levels
were measured on treatment with both statins.
Results: Both treatments were well tolerated in 247 patients (age 55.7 ± 11.1 years; 100 male; 140 with FH) with good
treatment compliance. There were statistically significant differences (P < 0.001) for rosuvastatin versus simvastatin for
LDL-C reduction (−52.4 ± 11.9 % vs. -47.7 ± 10.8 %) and on-treatment LDL-C (2.62 ± 0.99 mmol/L vs. 2.86 ± 0.97 mmol/L),
respectively, but the on-treatment hsCRP levels (1.33 ± 1.37 mg/L vs. 1.41 ± 1.57 mg/L, P > 0.05) were not significantly
different. The lipid target (LDL-C <2.6 mmol/L) was achieved by 52.9 % with rosuvastatin compared with 42.6 % with
simvastatin (P < 0.05). The proportions of patients attaining hsCRP targets of <2 and <1 mg/L were similar with the two
statins (57.1 % and 74.6 % for rosuvastatin vs. 57.1 % and 80.1 % for simvastatin, P > 0.05).
Conclusion: A significantly greater proportion of patients achieved LDL-C targets with rosuvastatin 10 mg compared to
simvastatin 40 mg in Chinese patients with hypercholesterolaemia, but there was no significant difference in achieving
hsCRP target levels with the two statins.
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Introduction
The significant cardiovascular benefits of statins have
been proven in many large randomized clinical trials and
these benefits are thought to be largely mediated by their
effect on reducing plasma low-density lipoprotein chol-
esterol (LDL-C) concentrations. Other pleiotropic effects
such as anti-inflammatory and anti-oxidative effects may
also be involved [1, 2]. These large clinical trials showed
that every 1 mmol/L reduction in LDL-C with statin
therapy was associated with a proportional reduction of
about 20 % in major vascular events [3] and more inten-
sive statin therapy with greater reductions in LDL-C of
2–3 mmol/L might reduce the incidence of major vascu-
lar events by 40-50 % [4]. Based on this accumulated
evidence, lipid guidelines have advocated lower LDL-C
targets [5–7].
Inflammation plays a fundamental role in the patho-
genesis of atherothrombotic disease [8, 9]. Prospective
observational studies showed that a raised concentration
of high-sensitivity C-reactive protein (hsCRP), a well-
known and extensively studied systemic biomarker of
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inflammation, was associated with increased risk of vas-
cular disease and mortality [10], although whether this
association is causal or indicative of another underlying
risk factor is still controversial [11]. Statin therapy
reduces hsCRP levels in a wide range of patients and
some studies demonstrated that patients who had lower
hsCPR levels with statin therapy had greater clinical
benefits [12–14]. The large JUPITER (Justification for
the Use of statins in Primary prevention: an Intervention
Trial Evaluating Rosuvastatin) study has shown that the
reductions in LDL-C and hsCRP with rosuvastatin treat-
ment were independent predictors of the vascular bene-
fits of statin treatment and the reductions in LDL-C and
hsCRP in individual patients were not significantly cor-
related suggesting that the change in hsCRP levels with
statin is independent of the change in LDL-C [14]. The
result of the JUPITER trial prompted the United States
Food and Drug Administration to approve the use of
rosuvastatin in subjects (>50 years in men; >60 years in
women) with elevated hsCRP levels (>2 mg/L) and at
least one additional cardiovascular risk factor in early
2010 [15].
Simvastatin and rosuvastatin are two commonly used
statins worldwide with the doses of 40 mg simvastatin
or 10 mg rosuvastatin being commonly prescribed in
Chinese patients with increased cardiovascular risk and
higher levels of LDL-C. Lower doses of 2.5 and 5 mg
rosuvastatin are considered more standard in Japan and
have been shown to slow coronary plaque progression
[16], but higher doses are probably needed to produce
regression of coronary plaque volume [17]. It has been
shown that on average rosuvastatin 10 mg daily has a
more potent effect on reducing LDL-C than that of
simvastatin 40 mg [18, 19], but there is no study com-
paring the effect of these two statins on hsCRP which
may involve pathways which differ from those involved
in lowering LDL-C. This study examined the LDL-C
and hsCRP goal attainment with simvastatin and rosu-
vastatin in Chinese patients with hypercholesterolaemia.
Methods
This study analysed data from Chinese patients with
hypercholesterolaemia who received both rosuvastatin
and simvastatin in an open-label, crossover study per-
formed to assess the pharmacogenetics of responses as
described previously [18]. In brief, the study subjects
were Hong Kong Han Chinese patients aged at least
18 years with established coronary heart disease (CHD)
or CHD risk equivalent [6], including some with hetero-
zygous familial hypercholesterolaemia (FH). Individuals
with uncontrolled diabetes, hypertension or thyroid dis-
ease, significant renal or hepatic dysfunction, those who
had experienced a cardiovascular disease (CVD) event
within the 3 months before recruitment, or those with
poor adherence with statin therapy (reporting taking <80 %
of the prescribed number of tablets) were excluded. There
were 177 patients taking rosuvastatin 10 mg daily and 70
patients taking simvastatin 40 mg as initial treatment.
Baseline and on-treatment lipid profiles and on-treatment
hsCRP levels were measured after at least 4 weeks treat-
ment for each statin. Thereafter, patients were switched to
the other statin for at least 4 weeks with lipid and hsCRP
levels being re-measured.
The study protocol was approved by the Clinical
Research Ethics Committee and the study was per-
formed in accordance with the Declaration of Helsinki.
All participants gave their written informed consent.
Laboratory analysis
The lipid and laboratory safety parameters were mea-
sured by routine methods. The plasma hsCRP concen-
tration was determined using an immunonephelometric
method (Siemens Dade Behring CardioPhase hsCRP
assay, Newark, DE, USA) on the Siemens BN ProSpec®
System with the detection limit of 0.146 mg/L (the
measurement range was 0.146–9.35 mg/L) and the
inter-assay coefficients of variation of 2.5, 3.8 and 2.1 %
at hsCRP concentrations of 0.500, 1.30 and 2.10 mg/L,
respectively.
Statistical analysis
Subjects with hsCRP levels >10 mg/L were excluded
from the analysis for hsCRP (n = 13) as this high level of
hsCRP is likely to be due to acute illness and for those
with hsCRP levels below the limit of detection, the value
of 0.1 mg/L was assigned. The on-treatment LDL-C and
hsCRP levels with the two statins and the percentage
change in lipids were compared by paired t-test or
Wilcoxon test wherever appropriate. According to the
Adult Treatment Panel III guideline, the overall LDL-C
goal for high-risk patients is <2.6 mmol/L with an optional
intensified LDL-C goal of <1.8 mmol/L for patients with
very high-risk [7]. Subjects were evaluated as to whether
they had attained the hsCRP goals of <2 mg/L or <1 mg/L.
The LDL-C and hsCRP goal attainments with the two
statins were compared by using a χ2 test. P value <0.05
was considered statistically significant. Data were ana-
lyzed with SPSS version 17.0 (SPSS Inc., Chicago, IL,
USA).
Results
Both treatments were well tolerated in 247 patients with
good compliance. The baseline characteristics of the
study participants are shown in Table 1. There was no
significant difference in baseline characteristics between
subjects with different statin treatment orders (data not
shown). The mean (±SD) age of the study subjects was
55.7 ± 11.1 years and 40.5 % (n = 100) of the study
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subjects were male. There were 140 patients having FH
who had significantly higher baseline levels of LDL-C
and HDL-C but lower triglycerides than those of non-
FH patients (Fig. 1).
There were significant differences (P < 0.001) for
rosuvastatin versus simvastatin for the on-treatment
LDL-C (2.62 ± 0.99 mmol/L vs. 2.86 ± 0.97 mmol/L,)
and the percentage reduction in LDL-C (−52.4 ± 11.9 %
vs. -47.7 ± 10.8 %), but not for the on-treatment hsCRP
levels (1.33 ± 1.37 mg/L vs. 1.41 ± 1.57 mg/L, P > 0.05)
in overall subjects and in subgroups of FH and non-FH
patients, respectively (Fig. 2). Body weight and waist cir-
cumference were not different whilst on the two statin
treatments (body weight: 64.1 ± 13.1 kg with rosuvastatin
and 64. ± 13.1 kg with simvastatin, P > 0.05; waist circum-
ference: 85.9 ± 11.6 cm vs. 85.3 ± 12.6 cm, P > 0.05)._
The on-treatment LDL-C and the on-treatment hsCRP
levels on rosuvastatin treatment were significantly corre-
lated with the respective values on simvastatin (r = 0.812
and r = 0.683, P < 0.001 for both), whereas there was no
correlation between the on-treatment LDL-C level or the
percentage reduction in LDL-C in response to either statin
and the on-treatment hsCRP levels (P > 0.05). There was
no difference in on-treatment LDL-C and hsCRP levels
with the two statins in patients receiving the statin treat-
ments in a different order of (data not shown).
The LDL-C targets of <2.6 mmol/L and <1.8 mmol/L
were achieved by 52.4 % and 20.3 % with rosuvastatin
compared with 43.3 % and 9.8 % with simvastatin in all
subjects (P < 0.05). The difference in LDL-C goal attain-
ment with the two statins was more significant in FH
patients (Fig. 3). There were higher proportions of non-
FH patients achieving the LDL-C goals with both statins
than FH patients, as FH patients had higher baseline
LDL-C levels (Fig. 3). The proportions of patients attain-
ing hsCRP goals of <2 and <1 mg/L with the two statins
or in patients with or without FH were not significantly
different (P > 0.05) (Fig. 3).
There were 39 % of patients achieving both targets for
LDL-C of <2.6 mmol/L and hsCRP <2 mg/L with rosu-
vastatin treatment compared to 28.1 % patients attaining
both targets with simvastatin treatment (P < 0.05).
Discussion
With the advantage of comparing two treatments in the
same subjects in a crossover design, this study showed
that a significantly (P < 0.05) greater proportion of patients
achieved LDL-C targets with rosuvastatin 10 mg com-
pared with simvastatin 40 mg in this group of Chinese
patients with increased cardiovascular risk. There were
81.1 % and 72.6 % of non-FH patients reaching the LDL-C
level of <2.6 mmol/L with rosuvastatin and simvastatin,
respectively. However, in patients with FH, lipid-lowering
monotherapy with rosuvastatin and simvastatin only
enabled 30.7 % and 20.9 % of patients to achieve the LDL-
C level of <2.6 mmol/L. Furthermore, there were no
patients who achieved the LDL-C goal of <1.8 mmol/L
with simvastatin treatment compared with 7.1 % who
achieved it with rosuvastatin. These results suggest that
higher statin doses or combination therapy is needed to
reach LDL-C goals in Chinese patients with FH, as in
other ethnic groups [20].
In a parallel group study in Greek patients with hyper-
lipidaemia, rosuvastatin 10 mg and simvastatin 40 mg
Table 1 Baseline characteristics of the study participants
All Males Females P
(n = 247) (n = 100) (n = 147)
Age, years 55.7 ± 11.1 55.0 ± 11.0 56.1 ± 11.3 0.425
FH, n (%) 140 (56.7) 53 (53.0) 87 (59.2) 0.336
Hypertension, n (%) 118 (47.8) 52 (52.0) 66 (44.9) 0.273
Type 2 diabetes, n (%) 48 (19.4) 24 (24.0) 24 (16.3) 0.135
History of CVD, n (%) 24 (9.7) 10 (10.0) 14 (9.5) 0.901
Current smoker, n (%) 26 (10.5) 24 (24.0) 2 (1.4) <0.001
CVD, cardiovascular disease; FH, familial hypercholesterolaemia
Fig. 1 Baseline lipid profiles on no lipid-lowering treatment in study subjects. Data are given as mean and error bars represent SD; *P < 0.005; **
P < 0.001 for FH vs. non-FH
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had similar effects on the reductions in both LDL-C and
hs-CRP and the combination of simvastatin 10 mg with
ezetimibe 10 mg also produced similar responses [21].
That finding may suggest that there is less difference in
the effects of these doses of the two statins on LDL-C in
Caucasians than in Chinese, which would be compatible
with the known ethnic differences in rosuvastatin
pharmacokinetics [22]. However, recent data from the
VOYAGER meta-analysis suggested that 10 mg rosuvas-
tatin is equivalent to approximately 70 mg simvastatin
for the effect on LDL-C [23].
Our results showed that there were 57.1 % of patients
having an on-treatment hsCRP level of <1 mg/L with both
of the statins and only 25.4 % and 19.9 % of patients had
hsCRP levels ≥2 mg/L with rosuvastatin and simvastatin,
respectively (P > 0.05). The hsCRP goal attainment was
comparable between patients with or without FH and is
greater than in patients in western countries [24], which is
probably due to a lower baseline hsCRP levels in East
Asian populations such as Japanese and Chinese [25].
Baseline hsCRP levels are largely determined by genetic
factors and obesity and both may contribute to the ethnic
differences in baseline hsCRP levels [26]. In a population-
based prospective cohort study in a general Japanese
population, higher hsCRP levels were significantly associ-
ated with a higher incidence of future CHD events even
Fig. 2 Baseline lipid profiles on no lipid-lowering treatment in study subjects. Data are given as mean and error bars represent SD. (a) On-treatment LDL-C
leves in all patients and in subgroups of FH and non-FH patients. (b) On-treatment hsCRP leves in all patients and in subgroups of FH and non-FH patients
Fig. 3 Proportion of subjects with on-treatment LDL-C of <2.6 and <1.8 mmol/L (a) and hsCRP <2 and <1 mg/L (b) with the two statins
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when the hsCRP level was below 1 mg/L [27]. Adiposity,
especially abdominal obesity, is the strongest predictor of
hsCRP concentrations across different populations [25],
probably resulting from obesity-induced up-regulation of
the cytokines IL-6 and TNF-α which contributes to low-
grade inflammatory and hsCRP elevation [28]. As Asians
have lower cutoff-points for waist circumference and body
mass index to define obesity and metabolic syndrome, as
recommended by the World Health Organisation [29], it
may also be appropriate to have lower hsCRP goals in
these East Asian populations.
Current evidence suggests that there is no relationship
between the reductions in LDL-C and in hsCRP in
response to the statin treatments in individual patients
[14, 30, 31]. Similar results were found in Japanese
patients treated with pitavastatin [32], and also with
atorvastatin [33]. However, a previous meta-analysis
which did not include the JUPITER trial demonstrated a
strong relationship between average changes in LDL-C
and CRP (r = 0.80, P <0.001) in healthy subjects and sub-
jects with stable coronary artery disease who were
treated with LDL-lowering interventions in placebo-
controlled trials [34], but this meta-analysis was per-
formed using mean levels of LDL-C and CRP changes in
each trial and this may not reflect the true correlation
between the changes in LDL-C and CRP in individuals.
Another study from Greece demonstrated correlations
between CRP reduction and the lipid-lowering effects of
simvastatin within Caucasian patients who were receiv-
ing chronic haemodialysis [35], but they may represent
an unusual group. The present study did not examine the
correlation between the changes in LDL-C and hsCRP in
response to the two statins as the baseline hsCRP level
was not available which is one of the main limitations of
the study. However, the stronger correlation between the
LDL-C values on the two statin treatments compared to
that between the hsCRP values on the two statin treat-
ments and the wide range of hsCRP values on statin treat-
ments suggests that the hsCRP changes with statin
treatments are more variable than the LDL-C changes.
In contrast to achieving maximum lipid-lowering ef-
fect after at least 4 weeks treatment, statins appear to
exert anti-inflammatory and beneficial endothelial effects
more rapidly, even after a single dose [36]. For instance,
a single 80 mg loading dose of atorvastatin within 24 h
of percutaneous coronary intervention reduced the inci-
dence of peri-procedural myocardial infarction [37]. Our
previous data showed that the ABCG2 421C > A poly-
morphism plays an important role in determining the
on-treatment level and LDL-C response to rosuvastatin
in Chinese patients but this polymorphism had no effect
on the hsCRP on-treatment levels in this group of
subjects [26, 38]. The recent genome-wide analysis in
over 3000 subjects of European ancestry who had been
randomly allocated to rosuvastatin 20 mg or placebo
daily in the JUPITER study also confirmed that a poly-
morphism (rs1481012) in ABCG2 which is in nearly
complete linkage disequilibrium (LD) with the ABCG2
421C > A polymorphism was the only pharmacokinetic-
related variant significantly associated on a genome-
wide basis with the LDL-C reduction in response to
rosuvastatin [39]. This genetic polymorphism together
with several other polymorphisms associated with the
LDL-C response to rosuvastatin identified in the JUPI-
TER study had no impact on the rosuvastatin-induced
hsCRP reduction after correction for multiple testing
[40]. This result further supports the hypothesis that
statin-mediated effects on inflammation as measured by
hsCRP are independent of statin-mediated effects on
LDL-C and less influenced by the statin pharmacokinetics.
Some clinical studies showed that higher doses of sta-
tins may reduce the hsCRP levels more than lower doses
of statins in patients with diabetes or stable coronary
disease [41, 42]. However, our study and the JUPITER
study showed that patients with the ABCG2 421A vari-
ant allele with increased systemic exposure to rosuvasta-
tin had similar hsCRP on-treatment level or hsCRP
reduction in response to rosuvastatin as those patients
without the variant allele suggesting that some other
genetic and/or environmental factors may affect the
hsCRP lowering effect in response to statins. The dosage
of statins used in our study might be considered as rela-
tively high in some Asian countries. However, previous
studies in Japan have shown that rosuvastatin 10 mg re-
sults in reductions in LDL-C of approximately 50 %
which is similar to our study [43, 44]. In the STELLAR
Trial, which compared different doses of rosuvastatin
and other statins, the LDL-C reduction with rosuvastatin
10 mg was 45.8 % and with simvastatin 40 mg was
38.8 % in a mainly Caucasian Group [45]. These values
are both less than the LDL-C reductions seen in the
Hong Kong patients, probably because the STELLAR
Trial used an intention to treat analysis whereas the
Hong Kong patients were selected for having good com-
pliance with therapy. Furthermore, it was shown that
this degree of LDL-C reduction is needed to achieve re-
gression of coronary atheroma in Japanese patients [17].
The present study showed there was no difference in
hsCRP levels with the two statins with different potency
in reducing LDL-C levels in this patient group. Rosen et
al. have reported that although switching to ezetimibe/
simvastatin (10/20 mg) was more effective at reducing
LDL-C vs. doubling the baseline statin dose to simva-
statin 40 mg or atorvastatin 20 mg or switching to rosu-
vastatin 10 mg, the combination therapy was not
superior to statin monotherapy in reducing hsCRP [46].
Interestingly, another study demonstrated that despite
having similar lipid-lowering potency, atorvastatin 10 mg
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resulted in greater reductions hsCRP and its variability
compared with simvastatin 40 mg in type 2 diabetic
patients [47]. It has been shown that treatment with high-
dose (80 mg daily) atorvastatin for 2 weeks had no effect
on hsCRP levels in normolipidaemic subjects with normal
hsCRP levels although the LDL-C levels were significantly
reduced indicating baseline hsCRP levels may play an
important role in determining the statin-mediated hsCRP
reduction [48].
Conclusions
In conclusion, this study showed that a significantly
greater proportion of patients achieved LDL-C targets
with rosuvastatin 10 mg compared to simvastatin 40 mg
in Chinese patients with or without FH, but there was
no difference in hsCRP levels with the two statin treat-
ments with the majority of patients reaching hsCRP
levels of <2 mg/L. The study also suggested that more
intensive lipid-lowering treatments are needed to enable
more FH patients to reach their LDL-C goals.
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